Hybrid Closed-Loop Control With Smart Prandial Insulin Dosing in Type 1 Diabetes

University of Virginia

Status: Completed

Conditions: Type 1 Diabetes

Treatments: Device: Standard HCL System; Device: HCL System with Smart Bolus Calculator

Study type: Interventional

Funder types: Other

Identifiers

NCT04878120

4-CDA-2020-948-A-N (Other Grant/Funding Number)

210112

Details and patient eligibility

About

The objective of this study is to evaluate the safety and feasibility of a smart bolus calculator that adjusts insulin dosing for meals according to real-time insulin sensitivity (SI) in adolescents with type 1 diabetes (T1D) using a hybrid closed loop (HCL) system during an active week of diabetes camp.

Full description

This is a single center, double-blind, randomized, crossover trial. The study team will target enrollment of 30 adolescents (age 12 - <18 years) with T1D who currently manage their diabetes with an insulin pump and a continuous glucose monitoring (CGM) system. Participants will be randomized 1:1 to the use of the standard HCL system (USS Virginia) vs. the HCL system with the smart bolus calculator first. The trial will be held at a local camp facility and will consist of EITHER a weeklong (6 day/5 night) camp OR two long weekends (4 day/3 night) separated by a washout period of about one week.

Enrollment: 25 patients

Sex: All

Ages: 12 to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥12 and <18 years old at time of consent
2. Clinical diagnosis, based on investigator assessment, of T1D for at least one year
3. Currently using insulin for at least six months
4. Currently using an insulin pump for at least three months
5. Currently using a CGM system for at least three months
6. Having at least 75% of CGM data over the previous four weeks
7. Using insulin parameters such as carbohydrate ratio and correction factors consistently on their pump in order to dose insulin for meals or corrections
8. Access to internet and willingness to upload data during the study as needed
9. For females, not currently known to be pregnant or breastfeeding
10. A negative urine pregnancy test will be required for all females of childbearing potential
11. Willingness to suspend use of any personal CGM for the duration of the clinical trial once the study CGM is in use
12. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the study
13. Total daily insulin dose (TDD) of at least 10 U/day
14. Willingness not to start any non-insulin glucose-lowering agent during the course of the trial (including metformin, GLP-1 agonists, pramlintide, DPP-4 inhibitors, biguanides, sulfonylureas and naturaceuticals)
15. Willingness to eat at least 40 grams of carbohydrates per meal
16. An understanding and willingness to follow the protocol and signed informed consent
17. Participants and parent/legal guardians will be proficient in reading and writing in English
18. Willingness to comply with COVID-19 precautions as defined by the study team
19. Having completed a COVID-19 vaccination with an FDA-approved COVID-19 vaccine at least two weeks before the first study admission, and willing to provide a copy of the COVID-19 vaccination card

Exclusion criteria

1. Hemoglobin A1c <5% or >10% if measured at screening or available from historical medical report performed within the last 6 months; in absence of a valid HbA1c measurement, average blood glucose estimated from CGM data to be approximately between 100 and 240 mg/dL
2. History of diabetic ketoacidosis (DKA) in the 6 months prior to enrollment
3. Severe hypoglycemia resulting in seizure or loss of consciousness in the 6 months prior to enrollment
4. Pregnancy or intent to become pregnant during the trial
5. Currently breastfeeding or planning to breastfeed
6. Currently being treated for a seizure disorder
7. Planned surgery during study duration
8. History of cardiac arrhythmia (except for benign premature atrial contractions and benign premature ventricular contractions which are permitted)
9. Treatment with any non-insulin glucose-lowering agent (metformin, GLP-1 agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals)
10. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol.
11. Use of an insulin delivery mechanism that is not downloadable by the participant or study team
12. Known contact with COVID-positive individual within 14 days of any study admission without negative follow-up COVID-19 Polymerase Chain Reaction (PCR) test performed 3-5 days after the date of exposure
13. Symptoms of COVID-19 (e.g., fever, shortness of breath, unexpected loss of taste or smell) developed within 14 days of any study admission
14. A positive COVID-19 test within 14 days of any study admission or during study admission participation
15. Not being fully vaccinated at the time of the first camp admission (according to Center for Disease Control (CDC) guidelines a person is intended to be fully vaccinated after two weeks from either the second dose of the Pfizer or Moderna vaccine, or the single dose of the Johnson & Johnson vaccine)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

25 participants in 2 patient groups

Standard HCL System - HCL System with Smart Bolus Calculator

Other group

Description:

Use of standard HCL system followed by use of HCL system with smart bolus calculator informed by insulin sensitivity

Treatment:

Device: HCL System with Smart Bolus Calculator

Device: Standard HCL System

HCL System with Smart Bolus Calculator - Standard HCL System

Other group

Description:

Use of HCL system with smart bolus calculator informed by insulin sensitivity followed by use of standard HCL system

Treatment:

Device: HCL System with Smart Bolus Calculator

Device: Standard HCL System